Shi Ming, Zhang Chao, Wang Fu-Sheng
Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Infect Dis Immun. 2021 Apr 20;1(1):52-58. doi: 10.1097/01.ID9.0000733568.58627.47. eCollection 2021 Apr.
Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and SARS-CoV-2 infection (causing coronavirus disease 2019 [COVID-19]) are serious diseases. To date, no effective post-exposure prophylaxis, prevention, or therapeutic agents are recommended as effective for these diseases. Convalescent plasma (CP), donated by individuals with established humoral immunity to the virus after recovering from coronavirus infection, has been successfully applied to treat several infectious diseases, including SARS, MERS, and COVID-19. Nonetheless, there are obstacles and challenges to using CP that should be taken into account. In this review, we summarize the evidence derived from clinical attempts to treat COVID-19 with CP, which represents a promising therapy for severe coronavirus infection. Furthermore, we outline the remaining challenges and general issues that should be considered when using CP treatment for therapeutic or prophylactic purposes.
中东呼吸综合征（MERS）、严重急性呼吸综合征（SARS）和严重急性呼吸综合征冠状病毒2型感染（导致2019冠状病毒病[COVID-19]）都是严重疾病。迄今为止，尚无有效的暴露后预防、预防或治疗药物被推荐用于这些疾病。恢复期血浆（CP）由冠状病毒感染康复后对该病毒具有体液免疫的个体捐献，已成功应用于治疗包括SARS、MERS和COVID-19在内的多种传染病。尽管如此，使用CP仍存在一些障碍和挑战，需要加以考虑。在本综述中，我们总结了从临床尝试用CP治疗COVID-19中获得的证据，这是一种对严重冠状病毒感染有前景的治疗方法。此外，我们概述了在将CP治疗用于治疗或预防目的时应考虑的其余挑战和一般问题。
